NYSE - Nasdaq Real Time Price USD

Pfizer Inc. (PFE)

25.36

+0.10

(+0.40%)

As of 10:40 AM EDT. Market Open.

Pfizer Receives FDA Approval for Bleeding Disorder Treatment

Pfizer has received approval from the Food and Drug Administration for a rare genetic bleeding disorder treatment—the drug-maker’s first gene therapy to be approved in the U.S. The treatment, Beqvez, is for adults with moderate to severe hemophilia B—a disorder that prevents normal blood clotting—and will be available by prescription to eligible patients this quarter, according to the company. “Many people with hemophilia B struggle with the commitment and lifestyle disruption of regular FIX infusions, as well as spontaneous bleeding episodes, which can lead to painful joint damage and mobility issues,” said Adam Cuker, director of University of Pennsylvania’s Comprehensive Hemophilia and Thrombosis Program.

Barrons.com 1 hour ago

PFE
+0.40%
Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure

The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.

Investor's Business Daily 1 hour ago

PFE
+0.40%
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 2.21% and 2.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 1 hour ago

ABBV

PFE
+0.40%
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks

Put your money to work by investing in these three high-quality dividend stocks.

Motley Fool 2 hours ago

PFE
+0.40%
T
+1.15%
BNS
UPDATE 2-US FDA approves Pfizer's gene therapy for rare bleeding disorder

The U.S. Food and Drug Administration approved Pfizer's gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that typically requires regular infusions of a blood-clotting protein. People with hemophilia have a fault in a gene that regulates production of proteins called clotting factors, which can cause spontaneous as well as severe bleeding following injuries or surgery.

Reuters 3 hours ago

PFE
+0.40%
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B

NEW YORK, April 26, 2024--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var)

Business Wire 3 hours ago

PFE
+0.40%
Should You Buy Moderna Before May 12?

This ambitious biotech aims to launch 15 products over the coming five years.

Motley Fool 5 hours ago

MRNA

PFE
+0.40%
Wall Street plunges after US inflation shock

US stock markets plunged amid fears of stagflation in the American economy, which grew at its slowest pace in nearly two years just as inflation jumped.

The Telegraph 21 hours ago

^FTSE

PFE
+0.40%
BHP
Update: GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines

Update: GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines

PREMIUM
MT Newswires 21 hours ago

PFE
+0.40%
BNTX
Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma

Bristol-Myers Squibb’s market capitalization has dropped so much over the past year that it is now arguably no longer part of the big pharma club. After reporting disappointing earnings figures on Thursday, the company’s shares fell sharply, giving it a market capitalization of about $95 billion. The problem for Bristol-Myers is that its older blockbuster products, cancer drug Revlimid and blood thinner Eliquis, are expected to decline in the coming years and investors aren’t convinced that the company has enough growth drivers in the near term.

The Wall Street Journal 22 hours ago

REGN

PFE
+0.40%
BMY
+1.05%
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

Reuters yesterday

PFE
+0.40%
GSK

BNTX
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

Reuters yesterday

GSK

PFE
+0.40%
BNTX
UPDATE 1-Ad group WPP reports 1.6% drop in first-quarter organic growth

British ad group WPP reported a 1.6% drop in organic growth in the first quarter, lagging its major rivals, after it was hit by loss of business from healthcare client Pfizer and reduced spending by technology companies. WPP, which had already warned that any organic growth this year would be weighted towards the second half, on Thursday reiterated its guidance for flat to 1% growth this year, with a margin improvement of 20-40 basis points.

Reuters yesterday

PFE
+0.40%
Pfizer Declares Second-Quarter 2024 Dividend

NEW YORK, April 24, 2024--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company’s common stock, payable June 14, 2024, to holders of the Common Stock of record at the close of business on May 10, 2024. The second-quarter 2024 cash dividend will be the 342nd consecutive quarterly dividend paid by Pfizer.

Business Wire yesterday

PFE
+0.40%
Is Pfizer Stock A Sell As Shares Hit An 11-Year Low Amid The Search For Its Next Big Break?

Pfizer stock remains under pressure despite becoming one of the biggest names of the pandemic. Is PFE stock a sell?

Investor's Business Daily yesterday

PFE
+0.40%
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.

Zacks yesterday

PFE
+0.40%
LLY

AMGN
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 days ago

PFE
+0.40%
LLY
Better Buy: Pfizer vs. Viking Therapeutics

These two pharma stocks have followed distinct paths of late. Which is the better investment?

Motley Fool 3 days ago

PFE
+0.40%
VKTX
Pfizer vs Moderna battle over COVID vaccine patents begins in UK

Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday. Pfizer and its German partner BioNTech sued Moderna at London's High Court in September 2022, seeking to revoke patents held by Moderna, which hit back days later alleging its patents had been infringed. Moderna says Pfizer and BioNTech copied mRNA advances it had pioneered and patented well before the COVID-19 pandemic began in late 2019.

Reuters 3 days ago

MRNA

PFE
+0.40%
BNTX
Pfizer (PFE) Rises Higher Than Market: Key Facts

Pfizer (PFE) reachead $26.26 at the closing of the latest trading day, reflecting a +1% change compared to its last close.

Zacks 3 days ago

PFE
+0.40%

Performance Overview

Return	PFE	S&P 500
YTD	-10.59%	+6.94%
1-Year	-32.20%	+25.28%
3-Year	-26.13%	+22.03%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pfizer Inc. (PFE)

Pfizer Receives FDA Approval for Bleeding Disorder Treatment

Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure

AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates

Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks

UPDATE 2-US FDA approves Pfizer's gene therapy for rare bleeding disorder

U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B

Should You Buy Moderna Before May 12?

Wall Street plunges after US inflation shock

Update: GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines

Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma

UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

UPDATE 1-Ad group WPP reports 1.6% drop in first-quarter organic growth

Pfizer Declares Second-Quarter 2024 Dividend

Is Pfizer Stock A Sell As Shares Hit An 11-Year Low Amid The Search For Its Next Big Break?

Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for

Better Buy: Pfizer vs. Viking Therapeutics

Pfizer vs Moderna battle over COVID vaccine patents begins in UK

Pfizer (PFE) Rises Higher Than Market: Key Facts

Performance Overview